Business
Vivos Therapeutics Announces Pricing of $21M Initial Public Offering
HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”), a medical technology company that offers novel and proprietary
About this update from Vivos Therapeutics, Inc.
[{"type":"text","content":"HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $6.00 per share. The shares of common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “VVOS” on Friday, December 11, 2020. The aggregate gross proceeds to Vivos from the public offering are expected to be $21 million prior to deducting underwriting discounts, commissions and other estimated offering expenses. Vivos has granted the underwriters a 45-day option to purchase up to an additional 525,000 shares of common stock to cover over-allotments, if any. Roth Capital Partners is acting as lead book-running manager and representative of the underwriters for the offering. Craig-Hallum Capital Group and National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NasdaqCM:NHLD) are acting as co-managers of the offering. The Securities and Exchange Commission declared effective a registration statement on Form S-1 relating to these securities on December 10, 2020. A final prospectus relating to this offering will be filed with the Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, by emailing Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, Attn: Prospectus Department, telephone: 800-678-9147, or email at [email protected]; National Securities Corporation, 200 Vesey Street, 25th Floor, New York, NY 10281, telephone: (212) 417-3634 or by sending an e-mail to: [email protected]; or Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, Attn: Equity Capital Markets, telephone: 612-334-6300 or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the Securities and Exchange Commission's website at http://www.sec.gov. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the Securities and Exchange Commission for more comple...